Type and hit ENTER

ABOUT US

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.

OUR COMPANY

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.

NEATstik®, a rapid test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017. This achievement follows on from the launch of the ProteaseTag® Active Neutrophil Elastase Immunoassay in 2016. A range of other laboratory-based immunoassays and point-of-care tests designed for routine monitoring of chronic diseases are in development.

ProAxsis also offers a highly experienced team who can provide clinical trial support services in regard to the specific measurement of active proteases and other inflammatory biomarkers within clinical samples.

ProAxsis was founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, School of Pharmacy, Queen’s University Belfast. By September, ProAxsis had won the overall Northern Ireland Science Park’s 25K Award for entrepreneurialism and in February 2014, the first seed investment from partners NetScientific plc and QUBIS Ltd was secured. In September 2014, they were the first company in Northern Ireland to win a prestigious Horizon 2020 SME Instrument Award.

OUR TEAM

  • David Ribeiro

    Dr David Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and …

    Chief Executive Officer
  • Brian Walker

    Professor Brian Walker, a co-founder of ProAxsis Ltd., has over 30 years of experience in the design and synthesis of “Protease-Tags” for the identification …

    Chief Scientific Officer
  • Kelly Moffitt

    Dr Kelly Moffitt has extensive research experience in the role of host proteases involved in both inflammation and infection, particularly within various respiratory diseases …

    Chief Operating Officer
  • Darragh McCafferty

    Darragh McCafferty graduated in 2004 with a Master of Pharmacy degree from Queen’s University Belfast, and completed his pre-registration training in community pharmacy. In …

    R&D Scientist
  • Charlene Robb

    Charlene obtained a MPharm degree from Queens University Belfast (QUB) in 2010 before completing pre-registration training and qualifying as a pharmacist in 2011. She …

    Regulatory and R&D Scientist
  • Timothy Ferguson

    Timothy graduated from Queen’s University Belfast with a Master of Pharmacy degree in 2011. Following successful completion of pre-registration training, he returned to the …

    R&D Scientist
  • Brian Walker

    Professor Brian Walker, a co-founder of ProAxsis Ltd., has over 30 years of experience in the design and synthesis of “Protease-Tags” for the identification …

    Chief Scientific Officer
  • Lorraine Martin

    Lorraine Martin is a Professor of Biomolecular Sciences, School of Pharmacy, Queen’s University Belfast (QUB) and a co-founder of ProAxsis Ltd. As an expert …

    Co-founder, Senior Lecturer, Non-Executive Director
  • Francois Martelet, M.D.

    François Martelet, Chief Executive Officer, joined NetScientific Mid 2015. He brings over 20 years of biopharma experience and a proven track record of shaping …

    Chairman
  • David Ribeiro

    Dr David Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and …

    Chief Executive Officer
  • Brian Walker

    Professor Brian Walker, a co-founder of ProAxsis Ltd., has over 30 years of experience in the design and synthesis of “Protease-Tags” for the identification …

    Chief Scientific Officer
  • Ian Postlethwaite

    Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016. He brings over 14 years of biopharma experience and a proven track record of …

    Non-Executive Director
  • Lorraine Martin

    Lorraine Martin is a Professor of Biomolecular Sciences, School of Pharmacy, Queen’s University Belfast (QUB) and a co-founder of ProAxsis Ltd. As an expert …

    Co-founder, Senior Lecturer, Non-Executive Director
  • David Moore

    David is Investment Manager with QUBIS Ltd, the early stage investment fund responsible for the commercialisation of technology from The Queen’s University of Belfast. …

    Non-Executive Director
  • Ernest Schneider

    BOD for Portfolio Companies

    Non-Executive Director
  • Stuart Elborn

    Professor Elborn is Clinical Professor of Respiratory Medicine and Centre Director for Adult Cystic Fibrosis at the Royal Brompton Hospital, London. He was formerly …

    Clinical Professor of Respiratory Medicine and Centre Director for Adult CF, Royal Brompton Hospital.
  • James Chalmers

    Professor Chalmers is a Wellcome Trust Postdoctoral Fellow, Senior Clinical Lecturer and Honorary Consultant Respiratory Physician at the University of Dundee. He is chair …

    Wellcome Trust Postdoctoral Fellow, Senior Clinical Lecturer and Honorary Consultant Respiratory Physician at the University of Dundee
  • Mona Bafadhel

    Professor Mona Bafadhel is an Associate Professor in Respiratory Medicine and NIHR Post Doctoral Fellow at the University of Oxford and holds an Honorary …

    Associate Professor in Respiratory Medicine / Honorary Consultant Chest Physician at the University of Oxford
  • Patrick Flume

    Patrick Flume is a Professor of Medicine and Pediatrics at the Medical University of South Carolina. He oversees a rapidly growing CF Center, including …

    Professor of Medicine and Pediatrics at the Medical University of South Carolina
  • Scott Sagel

    Dr Sagel is a pediatric pulmonologist who focuses on airway inflammation and lung disease in children with cystic fibrosis and primary ciliary dyskinesia. He …

    Director of the University of Colorado CF Centre
  • Penny Agent

    Penny has worked at the Royal Brompton and Harefield NHS Foundation Trust since 1996 and is currently the Director of Rehabilitation and Therapies. Her …

    Director of Rehabilitation and Therapies at the Royal Brompton and Harefield NHS Foundation Trust
  • Marcus Mall

    Marcus Mall is professor of Paediatrics and director of the Department of Translational Pulmonology at the Heidelberg University Medical School, and head of the …

    Professor of Paediatrics / Director of the Department of Translational Pulmonology at the Heidelberg University Medical School / Head of Paediatric Pulmonology at the University Hospital Heidelberg.

INVESTORS

NetScientific plc

ProAxsis is a core subsidiary of NetScientific plc.

NetScientific identifies, develops and commercializes transformative biomedical and healthcare technologies originating from leading universities, teaching hospitals and research institutes, with a focus on United Kingdom and United States.

More information about NetScientific’s purpose, core strategy and investment model can be viewed on the

NetScientific web site

QUBIS Ltd.

QUBIS, established in 1984, was one of the first University investment companies in the UK and Ireland and had a goal of commercialising the research and development activities of Queen’s University through the formation of spin-out businesses.  Working with academic entrepreneurs, QUBIS Ltd has continued to grow a portfolio of shareholdings in viable companies that have succeeded on an international level.  Queen’s remains one of the top universities in the UK for the level of revenue generated by spin-out companies, and has created over 60 companies to date.

QUBIS web site

About Us | ProAxsis